Pharmaceuticals
Consecutive Monthly Loading Administrations of Aflibercept 8 Mg for Treatment-Naïve Exudative AMD
Hosoda S, Sakurada Y, Fukuda Y, et al
In this study, the authors investigated short-term outcomes of 3 consecutive monthly administrations of aflibercept 8 mg for treatment-naïve eyes with exudative age-related macular degeneration. Administration was safe and effective for resolving polyp regression and exudation, with significant BCVA improvement.
Previous Article
- • Deep Learning-Assisted Analysis of Biomarker Changes in Therapy-Resistant Neovascular Age-Related Macular Degeneration
- • Real-World Safety and Efficacy of 8 mg Aflibercept in nAMD
- • Case Report: Aflibercept for DME in Vitrectomized Eyes
- • Guideline Recommendations for Optimal Anti-VEGF Therapy in AMD
- • AI-Assisted Fluid Volume Analysis of Treatment-Naive nAMD in the Real World
- • Consecutive Monthly Loading Administrations of Aflibercept 8 Mg for Treatment-Naïve Exudative AMD
- • Outcomes of High-Dose Aflibercept in Exudative nAMD
- • PULSAR: Intravitreal Aflibercept 8 mg in nAMD
- • PHOTON: Intravitreal Aflibercept 8 mg in Diabetic Macular Edema
- • CANDELA: Aflibercept 8 mg in Patients With nAMD
